EATG » CHMP recommends extension of therapeutic indications for Celsentri

CHMP recommends extension of therapeutic indications for Celsentri

At its April meeting, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended an extension of therapeutic indications for Celsentri (maraviroc) with marketing authorisation holder ViiV Healthcare UK Limited.

Summary of opinion for Celsentri is available here.

Source:
EMA
News categories: HIV treatment, EMA/FDA